Priveq Investment VI holds a first and final close at SEK 2.5 billion hard cap

17 June, 2020

Priveq, a leading Nordic lower mid-market growth and buyout investor, has closed its sixth fund, Priveq Investment VI, at SEK 2.5 billion. The fund was significantly oversubscribed with strong backing from existing investors and substantial interest from new European and North American institutional investors.

The fund’s investor base consists of a diversified group of Nordic, European and North American investors including public and private pension funds, insurance companies, charitable foundations, endowments, public institutions, family offices and fund-of-funds.

“We are very grateful for the continued support from our existing investors and for the significant interest expressed by new investors, allowing us to run an efficient fundraising process despite an incredibly turbulent market environment. Priveq has over the last decades experienced multiple crises and, whilst each is unique, we have learned from previous market dislocations that they also come with opportunities and we look forward to investing the fund over the coming years.” says Louise Nilsson, Managing Partner.

We had our first investor meeting on March 17th, the same week authorities announced the Corona restrictions in Sweden. We managed to follow our time plan in a pure digital process, thanks to strong support from existing investors and established relationships built over many years with new investors.” says Magnus Hardmeier, Executive Chairman. 

Athos Partners acted as exclusive placement advisor to Priveq on the fundraising. Proskauer and Vinge acted as legal advisers.


For further information, please contact

Louise Nilsson

Partner & CEO

Phone: +46 8 459 67 63
Mobile: +46 70 950 95 50
Read more »

Louise Nilsson

Partner & CEO

Louise Nilsson is Partner and CEO. In addition to leading and developing Priveq, she is responsible for sourcing new investment opportunities, in which Priveq will contribute with growth and value creation as well as implement growth strategies in cooperation with other owners, the board and management.

Since Louise joined Priveq in 1998, she has, among others, been responsible for the ownership in Carmel Pharma, Hemtex, Swedish Orphan International and Vårdapoteket. She is currently a Director of the Boards in 21 Grams, CSAM Health, Metenova, Plint and Ports Group.

Prior to Priveq, Louise worked as chartered accountant for ÖhrlingsCoopers & Lybrand (current PwC) for nine years, with responsibility for small and medium-sized owner-led companies.

Louise holds a B.Sc. in Business Administration from Luleå University.